Drive for stem cell donors in Langley – Surrey Now-Leader
Surrey Now-Leader |
Drive for stem cell donors in Langley
Surrey Now-Leader More than 390,000 Canadians have joined the OneMatch Stem Cell and Marrow Network registry maintained by Canadian Blood Services, volunteering to be stem cell donors for any patient in need of a transplant, anywhere in the world. Right now, the … Surrey teen rallies stem cell donors to help with ‘desperate’ need for South AsiansLangley Times |
|
Cost-effectiveness of allergen immunotherapy evaluated
Medical Xpress … the researchers found that sublingual immunotherapy (SLIT) and subcutaneous immunotherapy would be considered cost-effective using the U.K. National Institute for Health and Clinical Excellence threshold of £20,000/quality-adjusted life-year (QALY). |
Lymphoma Hub |
CLL post-ibrutinib: CAR T-cell therapy shown to result in durable molecular remissions
Lymphoma Hub Use of anti-CD19 Chimeric Antigen Receptor (CAR) T-cell therapy in CLL previously treated with ibrutinib has recently been shown to induce ‘durable molecular remissions’ in a phase I/II open-label study. The study, published in the Journal of Clinical … |
NewsChannel5.com |
Using your own stem cells to help your body heal osteoarthritis
Medical Xpress It works like this: Stem cells are extracted from a patient with a needle—usually from abdominal fat (adipose tissue) or bone marrow within the hip—and placed into a centrifuge, where the sample is spun rapidly to isolate the stem cells and create a … Stem Cell Therapy can provide a surgery-free solution to knee and …Colorado Springs Gazette Innovative Medical Solutions: Stem Cell TherapyNewsChannel5.com Global Stem Cell Market – Positive long term growth outlook 2016 …Medgadget (blog) Blasting News –The Pharma Letter (registration) –Health Thoroughfare all 14 news articles » |
|
With New Patent, Cesca Eyes Faster, Less Costly CAR–T Cell Production
Genetic Engineering & Biotechnology News Chimeric antigen receptor T–cell receptor (CAR-T) and CAR-modified natural killer (CAR-NK) therapeutics can be produced faster and at less cost, Cesca Therapeutics says, through the cellular processing technology covered by a recently-awarded patent. |